Immunoepidemiological profiling of onchocerciasis patients reveals associations with microfilaria loads and ivermectin intake on both individual and community levels.

• Váldodahkkit: Kathrin Arndts (Dahkki), Sabine Specht (Dahkki), Alexander Y Debrah (Dahkki), Francesca Tamarozzi (Dahkki), Ute Klarmann Schulz (Dahkki), Sabine Mand (Dahkki), Linda Batsa (Dahkki), Alexander Kwarteng (Dahkki), Mark Taylor (Dahkki), Ohene Adjei (Dahkki), Coralie Martin (Dahkki), Laura E Layland (Dahkki), Achim Hoerauf (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Public Library of Science (PLoS), 2014-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Mass drug administration (MDA) programmes against Onchocerca volvulus use ivermectin (IVM) which targets microfilariae (MF), the worm's offspring. Most infected individuals are hyporesponsive and present regulated immune responses despite high parasite burden. Recently, with MDA programmes, the...